Back to top
more

Chemed (CHE)

(Real Time Quote from BATS)

$588.69 USD

588.69
49,033

+10.92 (1.89%)

Updated Oct 8, 2024 03:54 PM ET

After-Market: $587.22 -1.47 (-0.25%) 4:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 10% (25 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LabCorp (LH) to Expand Nonclinical Development With New Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.

Phibro (PAHC) Sales Hurt by Staffing Shortage Amid Pandemic

by Zacks Equity Research

Internationally, Phibro (PAHC) is registering growth in nutritional specialties driven by strong sales of dairy products.

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

by Zacks Equity Research

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes

by Zacks Equity Research

Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.

Thermo Fisher (TMO) New Facility to Advance Lab Products Supply

by Zacks Equity Research

Thermo Fisher's (TMO) new manufacturing facility will help the United States meet demand surges for vital laboratory products.

Abbott (ABT) Introduces New Next-Generation Infant Formula

by Zacks Equity Research

Abbott's (ABT) Similac 360 Total Care contains five different HMOs, similar to human breast milk, to support the health and development of an infant.

SmileDirectClub (SDC) Introduces Treatment Planning Software

by Zacks Equity Research

SmileDirectClub's (SDC) SmileOS will enable its affiliated network of state-licensed doctors to treat more patients, better predict tooth movements and visualize patients' treatment.

Abbott (ABT) Scales to a 52-Week High: What's Driving It?

by Zacks Equity Research

Strong performance by the Diabetes Care and Diagnostics businesses is driving the top line for Abbott (ABT).

Cardiovascular Systems (CSII) Business Down on COVID Resurgence

by Zacks Equity Research

According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.

Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida

by Zacks Equity Research

Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.

Omnicell (OMCL) Inks New Deal to Manage Controlled Substances

by Zacks Equity Research

Omnicell (OMCL), Fresenius Kabi collaborate to offer safe and efficient dispensing of controlled substances across hospitals and health systems in the United States.

Here's Why You Should Add Chemed (CHE) to Your Portfolio Now

by Zacks Equity Research

Robust performance across the Roto-Rooter segment and sequential growth in VITAS admissions are driving the top line for Chemed (CHE).

IDEXX (IDXX) CAG Placement Grows Globally, LPD Disappoints

by Zacks Equity Research

IDEXX' (IDXX) global Reference Lab businesses are robust driven by high same-store volume growth with strong gains across testing categories.

Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.

Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.

BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued

by Zacks Equity Research

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.

Avanos Medical (AVNS) Q3 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.

PacBio's (PACB) Q3 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

PacBio (PACB) sees strength in Q3 product revenues, led by robust consumable and instrument sales.

Chemed (CHE) Q3 Earnings Beat Estimates, Full-Year EPS View Up

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings and revenues in the third-quarter 2021, with a solid performance by the Roto-Rooter segment driving the top line.

Chemed (CHE) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Chemed (CHE) delivered earnings and revenue surprises of 13.45% and 1.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline

by Zacks Equity Research

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Chemed (CHE) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).